SLC22A12 and diabetes mellitus: In clinical practice antagonists of some membrane transporters are applied, in other words, in the treatment of diabetes mellitus the drugs (gliflozins) target the sodium-glucose cotransporter 2 (SGLT2, SLC5A2) in the kidney and prevent the reabsorption of glucose, or in patients with gout lesinurad, an inhibitor of URAT1 (SLC22A12) carrier is used to selectively inhibit uric acid reabsorption in the kidney [79,80].